A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate safety of SPM 962 in advanced PD
patients in a multi-center, open-label, non-controlled study following once-daily multiple
transdermal doses of SPM962 within a range of 4.5 to 36.0 mg (maximum treatment period: 54
weeks). Efficacy is also to be exploratory investigated.